glp-1 weight loss drug news november 2025 Weight-loss makers announce pricing agreement with Trump Poll: 1 in 8 Adults

A solution without needing prescriptions

Farr, S

Josies Takeaways GLP-1 microdosing refers to using a dose below the initiation or maintenance levels studied in large clinical trials

Husain M, Birkenfeld AL, Donsmark M et al

GLP-1 receptor agonists (semaglutide, dulaglutide, liraglutide) can cause fatigue through reduced caloric intake, gastrointestinal side effects, and metabolic adjustment

It is well established that overweight and obesity increase a persons risk of cardiovascular events, but the concept of treating obesity to reduce cardiovascular complications has been hampered by lack of evidence that lifestyle or pharmacologic interventions for overweight or obesity improve cardiovascular outcomes, says Dr